Display options
Cite
Sharma N, Zhao Q, Ni B, et al. Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation. Cancers (Basel). 2021;13(4)doi: 10.3390/cancers13040613.
Sharma, N., Zhao, Q., Ni, B., Elder, P., Puto, M., Benson, D. M., Rosko, A., Chaudhry, M., Devarakonda, S., Bumma, N., Khan, A., Vasu, S., Jaglowski, S., William, B. M., Mims, A., Choe, H., Larkin, K., Brammer, J., Wall, S., Grieselhuber, N., Saad, A., Penza, S., & Efebera, Y. (2021). Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation. Cancers, 13(4), . https://doi.org/10.3390/cancers13040613
Sharma, Nidhi, et al. "Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation." Cancers vol. 13,4 (2021). doi: https://doi.org/10.3390/cancers13040613
Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, Rosko A, Chaudhry M, Devarakonda S, Bumma N, Khan A, Vasu S, Jaglowski S, William BM, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y. Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation. Cancers (Basel). 2021 Feb 04;13(4). doi: 10.3390/cancers13040613. PMID: 33557088; PMCID: PMC7913846.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Feb 04;13(4). doi: 10.3390/cancers13040613.

Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation.

Cancers

Nidhi Sharma, Qiuhong Zhao, Bin Ni, Patrick Elder, Marcin Puto, Don M Benson, Ashley Rosko, Maria Chaudhry, Srinivas Devarakonda, Naresh Bumma, Abdullah Khan, Sumithira Vasu, Samantha Jaglowski, Basem M William, Alice Mims, Hannah Choe, Karilyn Larkin, Jonathan Brammer, Sarah Wall, Nicole Grieselhuber, Ayman Saad, Sam Penza, Yvonne Efebera

Affiliations

  1. Comprehensive Cancer Center Columbus, Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
  2. Department of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.

PMID: 33557088 PMCID: PMC7913846 DOI: 10.3390/cancers13040613

Abstract

Acute graft versus host disease (aGVHD) remains a leading cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HSCT). Tacrolimus (TAC), a calcineurin inhibitor that prevents T-cell activation, is commonly used as a GVHD prophylaxis. However, there is variability in the serum concentrations of TAC, and little is known on the impact of early TAC levels on aGVHD. We retrospectively analyzed 673 consecutive patients undergoing allo-HSCT at the Ohio State University between 2002 and 2016. Week 1 TAC was associated with a lower risk of aGVHD II-IV at TAC level ≥10.15 ng/mL (

Keywords: allogeneic stem cell transplantation; graft versus host disease; relapse; tacrolimus

References

  1. Nat Rev Clin Oncol. 2014 Sep;11(9):536-47 - PubMed
  2. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 - PubMed
  3. Biol Blood Marrow Transplant. 1998;4(3):157-63 - PubMed
  4. Bone Marrow Transplant. 2016 Apr;51(4):568-72 - PubMed
  5. Bone Marrow Transplant. 1995 Jun;15(6):825-8 - PubMed
  6. Bone Marrow Transplant. 2010 Jul;45(7):1161-6 - PubMed
  7. Science. 1999 Jul 16;285(5426):412-5 - PubMed
  8. Blood. 2001 Feb 1;97(3):631-7 - PubMed
  9. Biol Blood Marrow Transplant. 2010 Jan;16(1):28-34 - PubMed
  10. Bone Marrow Transplant. 2006 Nov;38(10):645-51 - PubMed
  11. Biol Blood Marrow Transplant. 2012 Feb;18(2):229-34 - PubMed
  12. Biol Blood Marrow Transplant. 2012 Mar;18(3):414-22 - PubMed
  13. Blood. 2005 Aug 1;106(3):1113-22 - PubMed
  14. Blood. 2012 Jan 5;119(1):296-307 - PubMed
  15. Int J Hematol. 2009 Jan;89(1):98-105 - PubMed
  16. Biol Blood Marrow Transplant. 2005 Feb;11(2):108-14 - PubMed
  17. Lancet Oncol. 2009 Sep;10(9):855-64 - PubMed
  18. Blood. 2000 May 1;95(9):2754-9 - PubMed
  19. Blood. 2000 Mar 1;95(5):1572-9 - PubMed
  20. Blood. 1991 Apr 1;77(7):1423-8 - PubMed
  21. N Engl J Med. 2016 Jan 7;374(1):43-53 - PubMed
  22. Blood. 1998 Oct 1;92(7):2303-14 - PubMed
  23. Blood. 2000 Sep 15;96(6):2062-8 - PubMed
  24. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):835-41 - PubMed
  25. Clin Pharmacokinet. 2014 Feb;53(2):123-39 - PubMed
  26. Blood. 1996 Dec 15;88(12):4601-10 - PubMed
  27. Br J Haematol. 2000 Jan;108(1):99-104 - PubMed
  28. Biol Blood Marrow Transplant. 1999;5(2):94-7 - PubMed
  29. Bone Marrow Transplant. 2009 Apr;43(8):643-53 - PubMed
  30. Bone Marrow Transplant. 2001 Jul;28(2):181-5 - PubMed
  31. Haematologica. 2010 Jun;95(6):989-95 - PubMed
  32. Nat Med. 2002 Jun;8(6):575-81 - PubMed

Publication Types